Examination of the effectiveness of bepotastine besilate administration to the inducer and itching of atopic dermatitis patients
Not Applicable
- Conditions
- atopic dermatitis
- Registration Number
- JPRN-UMIN000012187
- Lead Sponsor
- Juntendo University (Graduate School) hospital departoment dermatorogy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Atopic dermatitis patients with severe for example Cases it is necessary to continue using drugs that seem to affect the response evaluation of test agent within a week before, antiallergic agents, antihistamines, oral steroids, and cyclosporine oral medicine. Patients having serious complications liver disease, kidney disease, heart disease, and other attending physician deems inappropriate. Dialysis patients and patients taking opioid be assumed pruritus central. Potential cases of lactating women, pregnant or are pregnant. Other patients attending physician deems inappropriate incorporation into the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method QOL (Dermatology Life Quality Index) Pruritus (Visual Analog Scale) Safety and sleepiness (Visual Analog Scale) Severity (day skin simplified method) before Administered / after 2 weeks / 4 weeks
- Secondary Outcome Measures
Name Time Method Tryptase Cortisol TARC before Administered / after 2 weeks / 4 weeks